Arimoclomol & Ipique Developers To Make Their Case For EU Approval

Orphazyme & Rotterdam Biologics Are Scheduled To Present Before The EMA This Week

The sponsors of two investigational drugs that have previously experienced key regulatory setbacks are set to give oral explanations to the European Medicines Agency about why they believe their products should be approved in the EU.

eye with flag
EU approval is being sought for an ophthalmic bevacizumab drug • Source: Alamy

Orphazyme and Rotterdam Biologics are due to appear before the European Medicines Agency this week to explain why their respective investigational drugs – arimoclomol and Ipique (bevacizumab) – should be approved for marketing in the EU.

Both companies have previously experienced key regulatory setbacks for their products – Orphazyme in the US and Rotterdam Biologics in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography